- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent
- At second interim analysis, statistical success criteria not met. Favorable safety profile confirmed
- Initial analyses show trend for age and variant dependent efficacy
- Results communicated to EMA, study progressing to final analysis within the next few weeks
Wednesday, June 16, 2021
CureVac Updates on Phase 2b/3 Trial of First-Generation COVID-19 Vax, Misses Success Crfiteria
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.